Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV use in hospitalized patients during the EUA period are not well described.

Matéria original


Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase


No significant benefit of moderate-dose vitamin C on severe COVID-19 cases